Rapport Therapeutics spikes on RAP-219 Phase 2 bipolar-mania win; Jefferies sees $1B peak sales (Oct 20)
What happened
Rapport Therapeutics reported positive topline data from a 253-patient U.S. Phase 2 trial of RAP-219 in adults with acute bipolar I mania: the drug met its primary endpoint with a statistically significant 3.1-point placebo-adjusted improvement on the Young Mania Rating Scale at Week 3 (p=0.045), plus a 0.4-point benefit on the CGI-BP mania severity scale, with all 11 YMRS items numerically improved. Safety was the standout: all treatment-emergent adverse events were mild or moderate, with no severe or serious events — and crucially low sedation (somnolence) and no movement-disorder signals, differentiating it from existing mood stabilizers that are notoriously sedating. Rapport plans an FDA End-of-Phase 2 meeting in Q1 2027 and two Phase 3 trials starting in 2H 2027, with cash of $436.1M funding a runway into 2H 2029. The news was disclosed via an 8-K filed October 20 at 6:05 AM ET.
Why it matters & what’s next are part of Pro, along with the audio summary.
Start your free 14-day trialWho’s affected
- RAPP (Rapport Therapeutics) — spiked as much as 84% premarket, faded to close +4.4% at $29.87 as analysts parsed the modest effect size; the faded close shows the market is skeptical the efficacy edge alone justifies the pipeline. Peer XENE (Xenon Pharmaceuticals) rose 4.1% in sympathy. Analysts: Jefferies sees a potential $1B+ peak-sales bipolar-mania opportunity
- BTIG raised its target to $89 from $75 (Buy)
- Wells Fargo reiterated Buy. Broader biotech (XBI) gets a modest sentiment read-through, consistent with yesterday's Disc Medicine pop.